Pathophysiology of ischaemia-reperfusion injury;Patofiziologija ishemijsko-reperfuzijske ozljede

Lijecnicki Vjesnik

Volumn 128, Issue 3-4, 2006, Pages 87-95

  Sirotković Skerlev, Maja ^a   Pleština, Stjepko ^a   Bilić, Ivan ^a   Kovač, Zdenko ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Antioxidants pharmacology; Ishemic preconditioning; Reactive oxygen species metabolism; Reperfusion injury physiopathology, metabolism, prevention and control

Indexed keywords

CYTOKINE; REACTIVE OXYGEN METABOLITE;

HUMAN; ISCHEMIA; REPERFUSION INJURY; REVIEW; TISSUE INJURY;

ANIMALS; HUMANS; REPERFUSION INJURY;

EID: 33646809789     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985;312:159-63.
2. Parks DA, Bulkley GB, Granger DN. Role of oxygen free radicals in shock, ischemia, and organ preservation. Surgery 1983;94:428-32.
3. Fink MP. Reactive oxygen species as mediators of organ dysfunction caused by sepsis, acute respiratory distress syndrome, or hemorrhagic shock: potential benefits of resuscitation with Ringer's ethyl pyruvate solution. Curr Opin Clin Nutr Metab Care 2002;5:167-74.
4. Warner DS, Sheng H, Batinić-Haberle I. Oxidants, antioxidants and the ischemic brain. J Exp Biol 2004;207:3221-31.
5. Aliev G, Obrenovich ME, Seyidova D, de la Torre JC. Exploring ischemia-induced vascular lesions and potential pharmacological intervention strategies. Histol Histopathol 2005;20:261-73.
6. Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg 1999;68:1905-12.
7. Quintana M, Kahan T, Hjemdahl P. Pharmacological prevention of reperfusion injury in acute myocardial infarction. A potential role for adenosine as a therapeutic agent. Am J Cardiovasc Drugs 2004;4:159-67.
8. Kozuch PL, Brandt LJ. Review article: diagnosis and management of mesenteric ischaemia with an emphasis on pharmacotherapy. Aliment Pharmacol Ther 2005;21:201-15.
9. Defraigne JO, Pincemail J. Local and systemic consequences of severe ischemia and reperfusion of the skeletal muscle. Physiopathology and prevention. Acta Chir Belg 1998;98:176-86.
10. Blaisdell FW. The pathophysiology of skeletal muscle ischemia and the reperfusion syndrome: a review. Cardiovasc Surg 2002;10:620-30.
11. Muizelaar JP. Cerebral ischemia-reperfusion injury after severe head injury and its possible treatment with polyethyleneglycol-superoxide dismutase. Ann Emerg Med 1993;22:1014-21.
12. Odeh M. The role of reperfusion-induced injury in the pathogenesis of the crush syndrome. N Engl J Med 1991;324:1417-22.
13. Boyle EM Jr, Canty TG Jr, Morgan EN, Yun W, Pohlman TH, Verrier ED. Treating myocardial ischemia-reperfusion injury by targeting endothelial cell transcription. Ann Thorac Surg 1999;68:1949-53.
14. Haines M, Shenkin A. Use of antioxidants in surgery: a measure to reduce postoperative complications. Curr Opin Clin Nutr Metab Care 2002;5:665-70.
15. Pater son IS, Klausner JM, Pugatch R i sur. Noncardiogenic pulmonary edema after abdominal aortic aneurysm surgery. Ann Surg 1989;209:231-6.
16. Bown MJ, Nicholson ML, Bell PR, Sayers RD. Cytokines and inflammatory pathways in the pathogenesis of multiple organ failure following abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 2001;22:485-95.
17. Serracino-Inglott F, Habib NA, Mathie RT. Hepatic ischemia-reperfusion injury. Am J Surg 2001;181:160-6.
18. Norio K, Wikstrom M, Salmela K, Kyllonen L, Lindgren L. Ascorbic acid against reperfusion injury in human renal transplantation. Transpl Int 2003;16:480-5.
19. Land WG. The role of postischemic reperfusion injury and other non-antigen-dependent inflammatory pathways in transplantation. Transplantation 2005;79:505-14.
20. Kim YI. Ischemia-reperfusion injury of the human liver during hepatic resection. J Hepatobiliary Pancreat Surg 2003;10:195-9.
21. al-Qattan MM. Ischaemia-reperfusion injury. Implications for the hand surgeon. J Hand Surg 1998;23:570-3.
22. Gamulin S. Poremećaji energijskog metabolizma. U: Gamulin S, Marušić M, Kovač Z, ur. Patofiziologija. Zagreb: Medicinska naklada; 2002, str. 133-53.
23. Krvavica S, Gamulin S. Integralna reakcija stanice na ozljedu. U: Gamulin S, Marušić M, Kovač Z, ur. Patofiziologija. Zagreb: Medicinska naklada; 2002, str. 115-23.
24. Gamulin S. Stanični energijski naboj i funkcija mitohondrija. U: Gamulin S, Marušić M, Kovač Z, ur. Patofiziologija. Zagreb: Medicinska naklada; 2002, str. 108-9.
25. Hoffman JW Jr, Gilbert TB, Poston RS, Silldorff EP. Myocardial reperfusion injury: etiology, mechanisms, and therapies. J Extra Corpor Technol 2004;36:391-411.
26. Halliwell B. The biological significance of oxygen-derived species. U: Valentine JS, Foote CS, Greenberg A, Liebman JF, ur. Active oxygen in biochemistry. New York: Blackie Academic & Professional; 1995, str. 313-335.
27. McCord JM, Roy RS, Schaffer SW. Free radicals and myocardial ischemia. The role of xanthine oxidase. Adv Myocardiol 1985;5:183-9.
28. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 3. izd. New York: Oxford University Press; 2001, str. 22-4.
29. Nathan C. Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. J Clin Invest 2003;111:769-78.
30. Allen BS. The role of leukodepletion in limiting ischemia/reperfusion damage in the heart, lung and lower extremity. Perfusion 2002;17:11-22.
31. Pincemail J. Free radicals and antioxidants in human diseases U: Favier i sur. ur. Analysis of free radicals in biological systems. Basel: Birkhauser Verlag; 1995, str. 83-98.
32. Book WM. Carvedilol: a nonselective beta blocking agent with antioxidant properties. Congest Heart Fail 2002;8:173-7,190.
33. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 2001;53:135-59.
34. Marczin N, El-Habashi N, Hoare GS, Bundy RE, Yacoub M. Antioxidants in myocardial ischemia-reperfusion injury: therapeutic potential and basic mechanisms. Arch Biochem Biophys 2003;420:222-36.
35. Ratych RE, Bulkley GB. Free-radical-mediated postischemic reperfusion injury in the kidney. J Free Radic Biol Med 1986;2:311-9.
36. Palter MS. Free radical-mediated postischemic injury in renal transplantation. Ren Fail 1992;14:257-60.
37. Plestina S, Gamulin S. Kidney ischaemia-reperfusion injury and polyribosome structure. Nephron 2001;89:201-7.
38. Cotelle N. Role of flavonoids in oxidative stress. Curr Top Med Chem 2001;1:569-90.
39. Barta E, Pechan I, Cornak V, Luknarova O, Rendekova V, Verchovodko P. Protective effect of alpha-tocopherol and L-ascorbic acid against the ischemic-reperfusion injury in patients during open-heart surgery. Bratisl Lek Listy 1991;92:174-83.
40. Dingchao H, Zhiduan Q, Liye H, Xiaodong F. The protective effects of high-dose ascorbic acid on myocardium against reperfusion injury during and after cardiopulmonary bypass. Thorac Cardiovasc Surg 1994;42:276-8.
41. Lassnigg A, Punz A, Barker R i sur. Influence of intravenous vitamin E supplementation in cardiac surgery on oxidative stress: a double-blinded, randomized, controlled study. Br J Anaesth 2003;90:148-54.
42. Canbaz S, Duran E, Ege T, Sunar H, Cikirikcioglu M, Acipayam M. The effects of intracoronary administration of vitamin E on myocardial ischemia-reperfusion injury during coronary artery surgery. Thorac Cardiovasc Surg 2003;51:57-61.
43. Sochman J. N-acetylcysteine in acute cardiology: 10 years later: what do we know and what would we like to know?! J Am Coll Cardiol 2002;39:1422-8.
44. Polidori MC, Mecocci P, Frei B. Plasma vitamin C levels are decreased and correlated with brain damage in patients with intracranial hemorrhage or head trauma. Stroke 2001;32:898-902.
45. Cerwenka H, Bacher H, Werkgartner G i sur. Antioxidant treatment during liver resection for alleviation of ischemia-reperfusion injury. Hepatogastroenterology. 1998;45:777-82.
46. Bartels M, Biesalski HK, Engelhart K, Sendlhofer G, Rehak P, Nagel E. Pilot study on the effect of parenteral vitamin E on ischemia and reperfusion induced liver injury: a double blind, randomized, placebo-controlled trial. Clin Nutr 2004;23:1360-70.
47. Wijnen MH, Vader HI, Van Den Wall Bake AW, Roumen RM. Can renal dysfunction after infra-renal aortic aneurysm repair be modified by multi-antioxidant supplementation? J Cardiovasc Surg 2002;43:483-8.
48. Wijnen MH, Vader HL, Roumen RM. Multi-antioxidant supplementation does not prevent an increase in gut permeability after lower torso ischemia and reperfusion in humans. Eur Surg Res 2002;34:300-5.
49. Novelli GP, Adembri C, Gandini E i sur. Vitamin E protects human skeletal muscle from damage during surgical ischemia-reperfusion. Am J Surg 1997;173:206-9.
50. Filis KA, Georgopoulos SE, Papas SC, Votteas V, Bastounis EA. Therapeutic efficacy of flavonoids in oedema following reperfusion on acu-tely ischaemic legs. Int Angiol 1999;18:327-30.
51. Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 1993;21 (10 Suppl):S447-63.
52. Ferrari R. The role of TNF in cardiovascular disease. Pharmacol Res 1999;40:97-105.
53. Donnahoo KK, Shames BD, Harken AH, Meldrum DR. Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 1999;162:196-203.
54. Furuichi K, Wada T, Yokoyama H, Kobayashi KI. Role of cytokines and chemokines in renal ischemia-reperfusion injury. Drug News Perspect 2002;15:477-482.
55. Thomton AJ, Strieter RM, Lindley I, Baggiolini M, Kunkel SL. Cytokine-induced gene expression of a neutrophil chemotactic factor/IL-8 in human hepatocytes. J Immunol 1990;144:2609-13.
56. Chang MS, McNinch J, Basu R, Simonet S. Cloning and characterization of the human neutrophil-activating peptide (ENA-78) gene. J Biol Chem 1994;269:25277-82.
57. Pober JS. Warner-Lambert/Parke-Davis award lecture. Cytokine-mediated activation of vascular endothelium. Physiology and pathology. Am J Pathol 1988;133:426-33.
58. Jaeschke H, Farhood A. Neutrophil and Kupffer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver. Am J Physiol 1991;260:G355-62.
59. Schulz R, Aker S, Belosjorow S, Heusch G. TNFalpha in ischemia/reperfusion injury and heart failure. Basic Res Cardiol 2004;99:8-11.
60. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol 1998;274:R577-95.
61. Ding WX, Yin XM. Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury. J Cell Mol Med 2004;8:445-54.
62. Al-Mehdi AB, Fisher AB. Invited editorial on »tumor necrosis factor-alpha in ischemia and reperfusion injury in rat lungs«. J Appl Physiol 1998;85:2003-4.
63. Bhatia M, Moochhala S. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol 2004;202:145-56.
64. Chow CW, Herrera Abreu MT, Suzuki T, Downey GP. Oxidative stress and acute lung injury. Am J Respir Cell Mol Biol 2003;29:427-31.
65. Kovač Z, Gamulin S. Upala - odgovor akutne faze. U: Gamulin S, Marušić M, Kovač Z, ur. Patofiziologija. Zagreb: Medicinska naklada; 2002, str. 507-14.
66. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
67. Kovač Z, Gamulin S. Sustavni upalni odgovor i višesustavno zatajenje organizma. U: Gamulin S, Marušić M, Kovač Z, ur. Patofiziologija. Zagreb: Medicinska naklada; 2002, str. 514-16.
68. Abraham E, Wunderink R, Silverman H i sur. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995;273:934-41.
69. Yoshidome H, kato A, Edwards MJ, Lentsch AB. Interleukin-10 suppresses hepatic ischemia/reperfusion injury in mice: implications of a central role for nuclear factor kappaB. Hepatology 1999;30:203-8.
70. Huber TS, Gaines GC, Welborn MB 3rd, Rosenberg JJ, Seeger JM, Moldawer LL. Anticytokine therapies for acute inflammation and the systemic inflammatory response syndrome: IL-10 and ischemia/reperfusion injury as a new paradigm. Shock 2000;13:425-34.
71. Ghosh S, May MJ, Kopp EB. NF-kappaB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
72. Gamulin S. Poremećaji vjesničkih molekula i putova. U: Gamulin S, Marušić M, Kovač Z, ur. Patofiziologija. Zagreb: Medicinska naklada; 2002;69-73.
73. Yeh CH, Lin YM, Wu YC, Lin PJ. Inhibition of NF-kappaB activation can attenuate ischemia/reperfusion-induced contractility impairment via decreasing cardiomyocytic proinflammatory gene up-regulation and matrix metalloproteinase expression. J Cardiovasc Pharmacol 2005;45:301-9.
74. Brown M, McGuinness M, Wright T i sur. Cardiac-specific blockade of NF-škappaćB in cardiac pathophysiology: differences between acute and chronic stimuli in vivo. Am J Physiol Heart Circ Physiol 2005;289:H466-76.
75. Luedde T, Assmus U, Wustefeld T i sur. Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest 2005;115:849-59.
76. Souza DG, Vieira AT, Pinho Vi sur. NF-kappaB plays a major role during the systemic and local acute inflammatory response following intestinal reperfusion injury. Br J Pharmacol 2005;145:246-54.
77. Acosta J, Qin X, Halperin J. Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Des 2004;10:203-11.
78. Zhou W, Farrar CA, Abe K i sur. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest. 2000;105:1363-71.
79. Pemberton M, Anderson G, Vetvicka V, Justus DE, Ross GD. Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle. J Immunol 1993;150:5104-13.
80. Murohara T, Guo JP, Delyani JA, Lefer AM. Cardioprotective effects of selective inhibition of the two complement activation pathways in myocardial ischemia and reperfusion injury. Methods Find Exp Clin Pharmacol 1995;17:499-507.
81. Collard CD, Montalto MC, Reenstra WR, Buras JA, Stahl GL. Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. Am J Pathol 2001;159:1045-54.
82. Kilgore KS, Friedrichs GS, Homeister JW, Lucchesi BR. The complement system in myocardial ischaemia/reperfusion injury. Cardiovasc Res 1994;28:437-44.
83. Arumugam TV, Shiels IA, Woodruff TM, Granger DN, Taylor SM. The role of the complement system in ischemia-reperfusion injury. Shock 2004;21:401-9.
84. Arumugam TV, Shiels IA, Strachan AJ, Abbenante G, Fairlie DP, Taylor SM. A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int 2003;63:134-42.
85. Arumugam TV, Woodruff TM, Stocks SZ i sur. Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. J Hepatol 2004;40:934-41.
86. Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Tylor SM. Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemia-reperfusion in rats. J Surg Res 2004;116:81-90.
87. Arumugam TV, Shiels IA, Woodruff TM, Reid RC Fairlie DP, Tylor SM. Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. J Surg Res 2002;103:260-7.
88. de Zwaan C, Kleine AH, Diris JH i sur. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 2002;23:1670-7.
89. Patel MR, Granger CB. Pexelizumab: a novel therapy for myocardial ischemia-reperfusion. Drugs Today 2005;41:165-70.
90. Grace PA. Ischaemia-reperfusion injury. Br J Surg 1994;81:637-47.
91. Stewart DJ, Kubac G, Costello KB, Cemacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol 1991;18:38-43.
92. Watanabe T, Suzuki N, Shimamoto N, Fujino M, Imada A. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res 1991;69:370-7.
93. Kawamura E, Yamanaka N, Okamoto E, Tomoda F, Furukawa K. Response of plasma and tissue endothelin-1 to liver ischemia and its implication in ischemia-reperfusion injury. Hepatology 1995;21:1138-43.
94. Hur GM, Ryu YS, Yun HY i sur. Hepatic ischemia/reperfusion in rats induces iNOS gene transcription by activation of NF-kappaB. Biochem Biophys Res Commun 1999;261:917-22.
95. Scommotau S, Uhlmann D, Loffler BM, Breu V, Spiegel HU. Involvement of endothelin/nitric oxide balance in hepatic ischemia/reperfusion injury. Langenbecks Arch Surg 1999;384:65-70.
96. Koeppel TA, Thies JC, Schemmer P i sur. Inhibition of nitric oxide synthesis in ischemia/reperfusion of the rat liver is followed by impairment of hepatic microvascular blood flow. J Hepatol 1997;27:163-9.
97. Stephanou A. Role of STAT-1 and STAT-3 in ischaemia/reperfusion injury. J Cell Mol Med 2004;8:519-25.
98. Reed JC. Apoptosis mechanisms: implications for cancer drug discovery. Oncology 2004;18 (13 Suppl 10):11-20.
99. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-6.
100. Philchenkov A. Caspases: potential targets for regulating cell death. J Cell Mol Med 2004;8:432-44.
101. Townsend PA, Scarabelli TM, Pasini E i sur. Epigallocatechin-3-gallate inhibits STAT-1 activation and protects cardiac myocytes from ischemia/reperfusion-induced apoptosis. FASEB J 2004;18:1621-3.
102. Force T, Kuida K, Namchuk M, Parang K, Kyriakis JM. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. Circulation 2004;109:1196-205.
103. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-36.
104. Slenzel-Poore MP, Stevens SL, Xiong Z i sur. Effect of ischaemic preconditioning on genomic response to cerebral ischaemia: similarity to neuroprotective strategies in hibernation and hypoxia-tolerant states. Lancet 2003;362:1028-37.
105. Kersten JR, Schmeling TJ, Pagel PS, Gross GJ, Warltier DC. Isoflurane mimics ischemic preconditioning via activation of K(ATP) channels: reduction of myocardial infarct size with an acute memory phase. Anesthesiology 1997;87:361-70.
106. Pasupathy S, Homer-Vanniasinkam S. Ischaemic preconditioning protects against ischaemia/reperfusion injury: emerging concepts. Eur J Vasc Endovasc Surg 2005;29:106-15.
107. Bolli R, Becker L, Gross G i sur. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 2004;95:125-34.